You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm will partner with startup GeneproDx on thyroid cancer diagnostic development, while a separate agreement with Endpoint Health will entail CDx development for critical illness.
The deal with GeneproDx will focus on thyroid cancer, while the agreement with Endpoint Health will focus on CDx development for critical illnesses.
PerkinElmer will provide biochemical and genetic testing to support BioMarin's testing program aimed at Batten disease and mucopolysaccharidosis disorders.
The partnership will provide new point-of-care lipid testing devices to remote sites in Latin America, the Caribbean, and Asia-Pacific.
Caspr's assay can be transported at room temperature and performed without complex external equipment, making it ideal for low-resource environments.
The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.
Todos said that it has also expanded its distribution rights to 3D Medicines' SARS-CoV-2 testing products in Asia, North America, and other regions.
Through its Access to COVID-19 Tools-Accelerator program, or ACT-A, WHO hopes to quickly identify and scale up high performing rapid antigen-based diagnostics.
Todos said it believes that gaining access to a medical grade ventilator will bring further attention to its coronavirus tests.
The PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in various respiratory specimens including oropharyngeal swabs.